Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments
Federal regulators propose sweeping Medicare, Medicaid, and Marketplace anti-fraud reforms projected to save taxpayers nearly $90 billion.
Follow the latest CVS HEALTH CORPORATION (CVS) news and market headlines alongside the live CVS price. Stay informed on what's moving CVS.
Federal regulators propose sweeping Medicare, Medicaid, and Marketplace anti-fraud reforms projected to save taxpayers nearly $90 billion.
UnitedHealth Group Inc. (NYSE: UNH) shares are trading lower on Tuesday after Sen. Elizabeth Warren called for breaking up major healthcare conglomerates.
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
Warren targets CVS, UnitedHealth and Cigna over healthcare consolidation and corporate ownership structures.
RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $113 to $108.
CVS Health announced plans to separate into two independent publicly traded companies: one retaining Aetna health insurance and Caremark pharmacy benefit manager, while CVS Pharmacy operates the retail store network. The company raised 2026 guidance, achieved target leverage ahead of schedule enabling share buyback resumption, and saw improved Medicare Advantage profitability through disciplined pricing and medical cost management.
Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $123 to $112.
CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.
CVS Health has gained 1.7% over the past month, outperforming the S&P 500's -3.7% decline. The company is expected to report earnings of $1.11 per share for the current quarter with 21.6% year-over-year growth projected for the fiscal year. CVS recently beat consensus EPS estimates by 29.01% and revenue estimates by 3.2%, demonstrating a strong track record of outperformance. The stock has been assigned a Zacks Rank #2 (Buy) rating and is trading at a discount to peers with an A valuation grade.
CVS Health Corporation is featured as a #2 (Buy) ranked stock with a VGM Score of A, demonstrating strong momentum with shares up 1.7% over the past four weeks. Nine analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $8.21 per share and an average earnings surprise of +23.3%.
The article compares Booking Holdings and Target as consumer stocks for 2027 investment. Booking operates a high-margin digital travel platform with 97.38% gross margins, 13.4% revenue growth, and strong free cash flow of $9.1 billion. Target is a traditional retailer with 1,995 stores, lower margins at 3.5%, but strategic brand partnerships and an expected 6% sales growth. The analyst recommends Booking as the better buy, citing its cheaper forward P/E ratio (15.2x vs 15.8x), shift to a merchant model for higher margins, and strong financial position with $16 billion in cash.
CVS Health is entering a more constructive earnings phase as Aetna's medical benefit ratio improves, pharmacy operating income rises 10.6%, and operating cash flow reaches $15.32 billion. However, persistent pressure from pharmacy benefit management, medical membership declines, and reimbursement headwinds keep execution risk elevated through 2027.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CVS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.